IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON

Their core work

The Biomedical Research Foundation of the Academy of Athens (BRFAA) is Greece's premier biomedical research institute, conducting fundamental and translational research in immunology, genomics, neuroscience, and cardiovascular-metabolic disease. They specialize in unraveling disease mechanisms at the molecular and systems level — from autoimmunity and inflammation to cancer biomarkers and hematopoietic disorders. BRFAA contributes deep omics expertise (genomics, transcriptomics, proteomics) and computational biology capabilities to large European consortia, and has led projects on systemic lupus, field cancerization detection, and cardiovascular-depression comorbidity. They also serve as a key Greek node in pan-European research infrastructures such as the Human Brain Project and BBMRI-ERIC.

What they specialise in

How they've shifted over time

In their early H2020 period (2015–2018), BRFAA was heavily invested in large-scale neuroscience infrastructure through the Human Brain Project (brain simulation, neuroinformatics, neuromorphic computing) alongside foundational biomedical infrastructure work (CORBEL, BBMRI-ERIC). From 2019 onward, their focus shifted decisively toward disease-specific translational research — particularly biomarker discovery, inflammatory and autoimmune conditions, and cardiovascular-metabolic comorbidities. The transition reflects a move from contributing to broad research platforms toward leading targeted clinical-translational projects with direct patient impact.

BRFAA is moving toward precision medicine for inflammatory and cardiovascular diseases, combining multi-omics data integration with clinical biomarker validation — expect growing interest in AI-driven diagnostics and personalized therapy partnerships.

How they like to work

BRFAA operates primarily as an active research partner within large European consortia (27 of 39 projects as participant), but has demonstrated clear leadership capacity by coordinating 9 projects including their largest award (LUPUSCARE, EUR 2.3M). With 500 unique consortium partners across 47 countries, they are a well-connected hub in European biomedical research rather than a closed-network player. Their breadth of partnerships signals an organization comfortable integrating into diverse teams and contributing specialized expertise on demand.

BRFAA has collaborated with 500 unique partners across 47 countries, making them one of the most broadly connected biomedical research institutes in Greece. Their network spans Western and Southern Europe heavily, with significant reach into Southeast European and Eastern Mediterranean research communities through infrastructure projects like VI-SEEM and NI4OS-Europe.

What sets them apart

BRFAA combines the prestige and independence of the Academy of Athens with hands-on translational research capabilities that many national academies lack. Their distinctive strength is bridging computational/omics approaches with clinical disease research — they can contribute both the bioinformatics pipeline and the biological understanding, which makes them a one-stop partner for projects needing integrated molecular analysis. For consortium builders, they also offer a reliable Greek partner with proven track record across 39 H2020 projects and the institutional stability of a national academy.

Highlights from their portfolio

• LUPUSCARE
  Their largest coordinated project (EUR 2.3M) applying genomics and molecular taxonomy to develop precision therapies for systemic lupus — demonstrates their leadership in autoimmune disease research.
• TO_AITION
  Coordinated project (EUR 849K) tackling the immune-metabolic link between cardiovascular disease and depression using biomarkers — represents their recent strategic direction toward comorbidity research.
• HBP SGA1/SGA2/SGA3
  Continuous participation across all three phases of the EUR 1B+ Human Brain Project flagship, contributing brain reconstruction and neuroinformatics — signals long-term reliability as a consortium partner.